Walleye Capital LLC Makes New $681,000 Investment in REGENXBIO Inc. (NASDAQ:RGNX)

Walleye Capital LLC acquired a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 88,148 shares of the biotechnology company's stock, valued at approximately $681,000. Walleye Capital LLC owned about 0.18% of REGENXBIO at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the stock. GAMMA Investing LLC increased its stake in REGENXBIO by 273.1% in the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company's stock valued at $27,000 after buying an additional 2,510 shares during the period. FMR LLC lifted its position in shares of REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 1,656 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of REGENXBIO during the 4th quarter valued at approximately $54,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of REGENXBIO during the 4th quarter valued at approximately $79,000. Finally, Teacher Retirement System of Texas lifted its position in shares of REGENXBIO by 19.9% during the 4th quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company's stock valued at $97,000 after acquiring an additional 2,088 shares during the period. Hedge funds and other institutional investors own 88.08% of the company's stock.

REGENXBIO Stock Down 0.2 %

Shares of NASDAQ RGNX traded down $0.02 during trading on Monday, hitting $9.13. 462,540 shares of the company traded hands, compared to its average volume of 816,569. The company has a 50-day moving average price of $6.94 and a 200-day moving average price of $8.09. REGENXBIO Inc. has a 1 year low of $5.04 and a 1 year high of $17.52. The firm has a market capitalization of $457.57 million, a P/E ratio of -1.82 and a beta of 1.26.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, topping analysts' consensus estimates of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The firm had revenue of $21.21 million during the quarter, compared to analysts' expectations of $23.70 million. Research analysts predict that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

RGNX has been the subject of a number of research reports. Raymond James assumed coverage on shares of REGENXBIO in a research report on Friday, February 7th. They set an "outperform" rating and a $27.00 price target for the company. Leerink Partners set a $24.00 price objective on REGENXBIO in a research report on Tuesday, March 18th. Chardan Capital restated a "buy" rating and set a $52.00 price objective on shares of REGENXBIO in a research report on Thursday, March 20th. The Goldman Sachs Group cut their price objective on REGENXBIO from $14.00 to $12.00 and set a "neutral" rating for the company in a research report on Thursday, April 17th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $30.00 price objective on shares of REGENXBIO in a research report on Tuesday, January 21st. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, REGENXBIO presently has a consensus rating of "Moderate Buy" and a consensus target price of $31.63.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.